3.2 C
New York
Wednesday, February 1, 2023

Is Esperion Therapeutics Inc. (NASDAQ: ESPR) The Best Stock To Invest In?

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Esperion Therapeutics Inc. (ESPR) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.15%, to $6.68. The Esperion Therapeutics Inc. has recorded 8,794 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Stocks Info

Esperion Therapeutics Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $6.69 and fluctuated between $7.14 as its day high and $6.66 as its day low. The current market capitalization of Esperion Therapeutics Inc. is $494.32M. A total of 1.05 million shares were traded on the day, compared to an average of 1.93M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, ESPR has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 44,000 and the disposition of 0 shares. Over the last 12 months, there were 9 BUYs and 11 SELLs from insiders. Insiders purchased 323,406 shares during that period but sold 14,804.

In the most recent transaction, Looker Benjamin sold 6,347 shares of ESPR for 7.00 per share on Jan 18. After the transaction, the General Counsel now owns 64,453 company shares. In a previous transaction on Jan 18, Foody Joanne M. sold 1,191 shares at 6.99 per share. ESPR shares that Chief Medical Officer owns now total 106,944.

Among the insiders who sold shares, Foody Joanne M. disposed of 942 shares on Oct 18 at a per-share price of $7.69. This resulted in the Chief Medical Officer holding 108,135 shares of ESPR after the transaction. In another insider transaction, Warren Eric sold 107 shares at $7.69 per share on Oct 18. Company shares held by the Chief Commercial Officer now total 53,662.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for ESPR in the last 3 months, the mean price target is $11.00 with high estimates of $22.00 and low estimates of $3.00. In terms of 52-week highs and lows, ESPR has a high of $8.87 and a low of $3.28.

As of this writing, ESPR has an earnings estimate of -$0.92 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of -$0.86 per share and a lower estimate of -$0.98. The company reported an EPS of -$0.93 in the last quarter, which was 10.60% higher than expectations of -$1.04.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 11 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ESPR is Hold with a score of 3.25. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 3 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles